Innovative Health Care Models Prove Cost-Effective Amidst Pandemic Pressures

By HEOR Staff Writer

September 26, 2023

During the COVID-19 pandemic, hospitals faced immense pressure. Singapore was also grappling with a dengue outbreak, adding to the strain on hospital capacity. This situation led to the rapid implementation of novel care models to treat patients with acute, low-severity medical conditions.

Two of these models, the hospital-at-home (HaH) and ambulatory care team (ACT) models, were used to treat patients with dengue and chest pain respectively. The HaH model allowed patients to receive care at home, while the ACT model provided timely care in a clinic-style setting at the hospital’s emergency department.

An economic evaluation aimed to compare the personnel cost of these models with conventional hospital inpatient care. The results showed that the HaH and ACT models used less personnel time, resulting in reduced costs.

The HaH model for treating dengue was found to be slightly cheaper than conventional care, with estimated savings of 18 SGD per case. The ACT model for treating chest pain showed more significant savings, with an estimated reduction of 126 SGD per case.

These innovative health care models not only alleviate hospital pressure but also potentially reduce hospital-acquired infections, length of stay, and overall health care expenditure. However, a reliable cost analysis of these models remains a priority.

Reference url

Recent Posts

Surge in Obesity Intervention Costs in the Netherlands

By HEOR Staff Writer

February 3, 2026

Obesity intervention costs in the Netherlands have skyrocketed, with a Zorginstituut Nederland report detailing a €61.8 million rise from 2021 to 2024 ...
HPV Vaccination Benefits Portugal: A Cost-Benefit Analysis of Expansion Effects

By João L. Carapinha

February 2, 2026

What are the HPV vaccination benefits Portugal can expect from expanding coverage? HPV vaccination benefits Portugal by delivering strong economic returns. Extending the National Immunization Program (NIP) to adult males up to age 26 and unvaccinated women aged 18-26 yields benefit-cost ratios (B...
Expansion of Generic Medicines Authorization in Portugal
928 New Medicines Authorizations Boost Portugal's Health Access In 2025, Portugal's National Authority for Medicines and Health Products (